TALLAHASSEE, Fla. (Dec. 10, 2025) – Tallahassee Memorial HealthCare (TMH) is now offering Aquablation® therapy with the new HYDROS™ Robotic System, the next-generation platform to treat men with benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate.
BPH is an unfortunate reality of aging for millions of men and impacts urinary function, making it difficult to urinate and fully empty the bladder. Without timely treatment, BPH can lead to severe health issues such as permanent bladder or kidney damage, bladder stones and incontinence. The standard treatment option today is surgery, but this has been shown to impact sexual function and continence.
“With Aquablation therapy, our surgeons use real-time, ultrasound-guided, robotic-assisted waterjet technology to precisely target which prostate tissue to remove and which to preserve,” said Logan Van Wagenen, Vice President of Operations at TMH.“For patients, that means less risk, fewer side effects and better results.”
Urologist Francisco Carpio, MD, with TMH Physician Partners - Urology is the first physician at TMH to perform the Aquablation therapy. James Farrell, DO will also be performing this procedure. Both doctors completed specialized training to bring this advanced procedure to TMH.
"BPH is a widespread condition that severely compromises quality of life for countless men over age 50. Aquablation therapy represents a major advancement in how we treat this condition,” said Dr. Carpio. “The ability to tailor treatment to each patient’s unique anatomy while preserving critical functions is a game-changer for men’s health.”
Aquablation therapy is performed in the hospital under anesthesia and typically requires only an overnight stay. Backed by five years of clinical data and insights from over 50,000 procedures, Aquablation therapy provides durable symptom relief across prostates of all shapes and sizes.
For more information about Aquablation therapy at TMH, visit TMH.ORG/Aquablation.
# # #
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. Its HYDROS™ Robotic System is the next-generation, AI-powered platform for Aquablation® therapy, a BPH treatment clinically proven to deliver significant, durable symptom relief while preserving sexual function and continence in prostates of all shapes and sizes. The Company has developed a significant and growing body of clinical evidence, including numerous clinical studies and peer-reviewed publications, that support the benefits and clinical advantages of Aquablation therapy.
